Group Of Experts Looks At High Price Of Cancer Drugs
Prices of cancer drugs must be lowered to be affordable for patients and to maintain sound long-term healthcare policies, according to a group of chronic myeloid leukemia (CML) experts in a recent Blood journal editorial.
